Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded to “Strong-Buy” at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Sunday.

Separately, Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Up 0.3 %

NASDAQ:SUPN opened at $31.26 on Friday. The company has a fifty day moving average of $36.22 and a 200 day moving average of $35.17. Supernus Pharmaceuticals has a 52 week low of $25.53 and a 52 week high of $40.28. The firm has a market capitalization of $1.74 billion, a P/E ratio of 29.22 and a beta of 0.83.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the sale, the vice president now directly owns 10,149 shares of the company’s stock, valued at $402,915.30. This represents a 48.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,104 shares of company stock valued at $440,263. 9.30% of the stock is currently owned by company insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vident Advisory LLC grew its position in shares of Supernus Pharmaceuticals by 2.2% in the 4th quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock worth $520,000 after buying an additional 309 shares during the period. Summit Investment Advisors Inc. grew its position in shares of Supernus Pharmaceuticals by 7.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock worth $190,000 after buying an additional 369 shares during the period. Bank of Montreal Can grew its position in shares of Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock worth $275,000 after buying an additional 473 shares during the period. Exchange Traded Concepts LLC grew its position in shares of Supernus Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock worth $800,000 after buying an additional 560 shares during the period. Finally, HighTower Advisors LLC grew its position in shares of Supernus Pharmaceuticals by 7.3% in the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company’s stock worth $330,000 after buying an additional 624 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.